Nucleoside analogues for the treatment of chronic hepatitis B
The eosinophil as a therapeutic target in gastrointestinal disease
Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?
The treatment of irritable bowel syndrome
Effect of hepatitis C virus infection on mortality in dialysis
Phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast)
Endoscopic ablation of Barrett's oesophagus
Irritable bowel, smoking and oesophageal acid exposure
The usual medical care for irritable bowel syndrome
Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario
A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab
Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease
Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease
Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized-controlled trial
Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis
Oesophageal pH has a power-law distribution in control and gastro-oesophageal reflux disease subjects
Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor
CORRIGENDA
ERRATUM